OncoMatch/Clinical Trials/NCT05512481
Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma
Is NCT05512481 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Camrelizumab for melanoma.
Treatment: Camrelizumab — Neoadjuvant therapy is feasible in stage Ⅱ-Ⅲ melanoma, Carrelizumab combined with apatinib and temozolomide has synergistic antitumor effects and may improve pathological response.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Melanoma
Disease stage
Required: Stage Ⅱ, Ⅲ
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: chemotherapy
Patients who have or are currently undergoing additional chemotherapy
Cannot have received: radiation therapy
Patients who have or are currently undergoing additional...radiation therapy
Cannot have received: targeted therapy
Patients who have or are currently undergoing additional...targeted therapy
Cannot have received: immunotherapy
Patients who have or are currently undergoing additional...immunotherapy
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05512481 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage Ⅱ or Ⅲ is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages